Adenosine deaminase prefers a distinct sugar ring conformation for binding and catalysis: Kinetic and structural studies

被引:74
作者
Ford, H [1 ]
Dai, F [1 ]
Mu, L [1 ]
Siddiqui, MA [1 ]
Nicklaus, MC [1 ]
Anderson, L [1 ]
Marquez, VE [1 ]
Barchi, JJ [1 ]
机构
[1] NCI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1021/bi992112c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several recent X-ray crystal structures of adenosine deaminase (ADA) in complex with various adenosine surrogates have illustrated the preferred mode of substrate binding for this enzyme. To define more specific structural details of substrate preferences for binding and catalysis, we have studied the ADA binding efficiencies and deamination kinetics of several synthetic adenosine analogues in which the furanosyl ring is biased toward a particular conformation. NMR solution studies and pseudorotational analyses were used to ascertain the preferred furanose ring puckers (P, nu(MAX)) and rotamer distributions (chi and gamma) of the nucleoside analogues. It was shown that derivatives which are biased toward a "Northern" (3'-endo, N) sugar ring pucker were deaminated up to 65-fold faster and bound more tightly to the enzyme than those that preferred a "Southern" (2'-endo, S) conformation. This behavior, however, could be modulated by other structural factors. Similarly, purine riboside inhibitors of ADA that prefer the N hemisphere were more potent inhibitors than S analogues. These binding propensities were corroborated by detailed molecular modeling studies. Docking of both N- and S-type analogues into the ADA crystal structure coordinates showed that N-type substrates formed a stable complex with ADA, whereas for S-type substrates, it was necessary for the sugar pucker to adjust to a 3'-endo (N-type) conformation to remain in the ADA substrate binding site. These data outline the intricate structural details for optimum binding in the catalytic cleft of ADA.
引用
收藏
页码:2581 / 2592
页数:12
相关论文
共 59 条
  • [1] AGARWAL RP, 1979, BIOCHEM PHARMACOL, V26, P259
  • [2] ALBERT A, 1962, IONIZATION CONSTANTS
  • [3] ALBERTY RA, 1951, J BIOL CHEM, V193, P425
  • [4] Conformational analysis of the complete series of 2' and 3' monofluorinated dideoxyuridines
    Barchi, JJ
    Jeong, LS
    Siddiqui, MA
    Marquez, VE
    [J]. JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1997, 34 (01): : 11 - 29
  • [5] POTENTIAL ANTI-AIDS DRUGS - LIPOPHILIC, ADENOSINE DEAMINASE-ACTIVATED PRODRUGS
    BARCHI, JJ
    MARQUEZ, VE
    DRISCOLL, JS
    FORD, H
    MITSUYA, H
    SHIRASAKA, T
    AOKI, S
    KELLEY, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (05) : 1647 - 1655
  • [6] BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P426
  • [7] CRYSTAL AND MOLECULAR-STRUCTURE OF 9-BETA-D-ARABINOFURANOSYLADENINE
    BUNICK, G
    VOET, D
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1974, B 30 (JUL15): : 1651 - 1660
  • [8] PURINE METABOLISM OF LYMPHOCYTES - TARGETS FOR CHEMOTHERAPY DRUG DEVELOPMENT
    CARRERA, CJ
    SAVEN, A
    PIRO, LD
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1994, 8 (02) : 357 - 381
  • [9] Cheson B D, 1994, Curr Opin Hematol, V1, P268
  • [10] Cheson BD, 1998, SEMIN HEMATOL, V35, P14